0 186

Cited 4 times in

A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis

Authors
 Suk-Won Ahn  ;  In Soo Joo  ;  Byung-Jo Kim  ;  Jung-Joon Sung  ;  Sa-Yoon Kang  ;  Jeeyoung Oh  ;  Yang-Ki Minn  ;  Bum Chun Suh  ;  Sun-Young Oh  ;  Yoon-Ho Hong  ;  Tai-Seung Nam  ;  Jung Im Seok  ;  Young-Eun Park  ;  Ha Young Shin  ;  Eun Bin Cho  ;  Je-Young Shin  ;  Hung Youl Seok  ;  Jin-Sung Park  ;  Ju-Hong Min  ;  Jin-Myoung Seok  ;  Byoung-Joon Kim 
Citation
 JOURNAL OF THE NEUROLOGICAL SCIENCES, Vol.379 : 271-275, 2017 
Journal Title
 JOURNAL OF THE NEUROLOGICAL SCIENCES 
ISSN
 0022-510X 
Issue Date
2017
MeSH
Drug Therapy, Combination ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Male ; Middle Aged ; Myasthenia Gravis/drug therapy* ; Prednisolone/therapeutic use ; Prospective Studies ; Tacrolimus/adverse effects* ; Tacrolimus/therapeutic use* ; Time Factors
Keywords
ADR ; MG ; MGCS ; Myasthenia gravis ; Prednisolone ; Tacrolimus
Abstract
INTRODUCTION: Several clinical studies using tacrolimus revealed reasonable therapeutic mechanisms and efficacy in patients with myasthenia gravis (MG). However, long-period studies in a large number of patients with MG are limited; therefore, the aim of this study was to investigate the therapeutic efficacies and safety of tacrolimus in patients with MG during a 12-month follow-up period. METHODS: Tacrolimus was administered to 150 patients with MG who were recruited based on the inclusion criteria. Fifteen medical centers in Korea participated in this study. The efficacy of tacrolimus was assessed using MG composite scales (MGCS) and the prednisolone-sparing effect. And the adverse drug reactions (ADRs) of tacrolimus were monitored in each patient from the beginning of tacrolimus treatment to the end of the follow-up period. RESULTS: After starting tacrolimus, the 32 patients were affected by ADRs, and consequentially 134 patients of the enrolled patients were followed up for 12months. They showed that the mean prednisolone dosage significantly decreased (6.1±7.6mg/day), compared to that in the baseline (11.3±9.5mg/day), and MGCS significantly improved after 12months of tacrolimus treatment, compared to that at the baseline. CONCLUSIONS: Our study showed that tacrolimus would be an effective immunosuppressant as an initial therapeutic agent in patients with MG; in addition, it showed tolerable safety profiles during the 12-month follow-up evaluation.
Full Text
https://www.sciencedirect.com/science/article/pii/S0022510X17303672
DOI
10.1016/j.jns.2017.05.060
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
Yonsei Authors
Shin, Ha Young(신하영) ORCID logo https://orcid.org/0000-0002-4408-8265
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/160564
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse